Sentences with phrase «immunogenicity studies»

As partner of TRANSVAC, IRTA will provide access to their animal facilities (CReSA) to carry out safety and immunogenicity studies of new candidate vaccines and / or of novel vaccination (administration) strategies in pigs, ferrets and other large animal species.

Optional: additional groups of ferrets for lung / tissues; virus neutralisation titres; histopathology; immunogenicity studies.

Researchers seek to sustain or increase this effect, and these clinical trials will enable them to collect more data and samples for immunogenicity studies.

Not exact matches

Although Tdap has an excellent safety record, future cohort or surveillance studies must continue to assess safety and immunogenicity of Tdap immunization during pregnancy, write Natalia Jimnez - Truque, M.S.C.I., Ph.D., and Kathryn M. Edwards, M.D., of Vanderbilt University Medical Center, Nashville, Tenn., in an accompanying editorial.

According to Dr Won Park, Inha University Hospital, Korea, and lead investigator of the PLANETAS study, «the challenge for biosimilars is to demonstrate similarity in therapeutic effectiveness, safety and immunogenicity to their reference product, not just biochemical and pharmacokinetic equivalence.»

The study, which was published in the last issue of Science Translational Medicine, reports early plasma cytokine signatures that correlate with, and predict, the immunogenicity and reactogenicity of the vaccine.

The European research collaboration behind this study focuses on deep immunological analysis of the immunogenicity and reactogenicity of the Ebola vaccine in healthy volunteers.

The next steps for this vaccine are to produce a clinical grade lot and conduct a phase 1 study of safety and immunogenicity in infants, Moore says.

Next to this, WBVR offers the use of its infrastructure to perform immunogenicity and efficacy studies for newly developed vaccines.

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS.

We produce live and inactivated viruses in our BSL2 and BSL3 facilities, and perform immunogenicity and efficacy studies in pigs (influenza) and sheep (RSV) with a focus on skin vaccination and extended monitoring of humoral and cellular immune responses in the blood and lung.

CAMBRIDGE, Mass., April 27, 2017 — Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) Therapeutics ™ to create a new generation of transformative medicines for patients, today announced positive interim data from an ongoing Phase 1 study of mRNA - 1440, an mRNA infectious disease vaccine against avian H10N8 influenza, demonstrating mRNA - 1440 induced high levels of immunogenicity, and was safe and well tolerated.

One hundred children aged 1 to 6 years were sequentially assigned to 3 cohorts of 20, 40 and 40 participants with stratification for age by 2 - year increments (1 — 2 years, 3 — 4 years, and 5 — 6 years) to ensure that the study groups were balanced by age in case of age - related differences in tolerability or immunogenicity.

Vaccine studies in infants < 6 mo with novel vaccine candidates have generally demonstrated poor immunogenicity (90).

The development track will begin with a Phase I trial to test the vaccine regimen's safety and immunogenicity and depending on those study results, a larger efficacy study will follow.

The randomized, double - blind, placebo - controlled study will evaluate the safety and tolerability of multiple doses of NPT088, as well as pharmacokinetics, immunogenicity and pharmacodynamic characteristics, as measured by Aβ and tau PET imaging.

MHRP, which led the RV144 trial with the Thai Ministry of Public Health, initiated follow - on clinical studies to conduct intensive immunogenicity research.

The overall objective of the current study was to identify an optimal pediatric dose of FMP2.1 / AS02A that is safe, with high immunogenicity and acceptable reactogenicity, for progression to efficacy testing.

Along with collaborators, the Weiner Lab was the first to move DNA vaccines to human clinical studies, establishing their initial safety and immunogenicity.

WRAIR and collaborators will share data related to assays designed to measure antibody responses following vaccination with ZPIV, biologic samples generated during the performance of animal studies, and biologic samples generated during the performance of early human trials assessing the safety and immunogenicity of ZPIV.

The results obtained by this service may be part of the documentation provided to other analytical services (TNA3), Adjuvants and delivery systems (TNA2) or Immunogenicity and efficacy studies (TNA8) as well as the Pre-clinical GLP production services (TNA4) and the GMP production services (TNA5).

Within the framework of TRANSVAC2, the HZI will offer access in the form of pre-clinical studies in the murine system to assess the immunogenicity, safety and efficacy of specific vaccine formulations.

Once recombinant vaccine antigens produced by this service are available, they could be forwarded to Analytical services (TNA3), Adjuvants and delivery systems (TNA2) or Immunogenicity and efficacy studies (TNA8), if applicable.

Immunogenicity and efficacy studies in pig (influenza) and sheep (RSV) with a focus on skin vaccination and extended monitoring of humoral and cellular immune responses in the blood and lung.

PFIE will provide access to its facilities for immunogenicity and efficacy studies in pigs or sheep (as well as other species if needed), according to users» requirements.

Furthermore serum samples or immune Ig preparations generated in the context of immunogenicity and challenge studies performed under the umbrella of the «Animal Models» could be analysed.

As partner of TRANSVAC2, WBVR will provide access to their animal facilities (Lelystad) to carry out immunogenicity and efficacy studies of new candidate vaccines and / or of novel vaccination (administration) strategies in pigs, cattle, ferrets or other animal species.

Within the framework of TRANSVAC2, the HZI will offer access in the form of pre-clinical studies in the murine system to assess the immunogenicity, safety and efficacy of specific vaccine formulations containing a mucosal adjuvant.

SSI offers vaccination studies in mice including 1 - 2 control groups and full immunogenicity analysis including CMI and humoral immunogenicity using Flow cytometry (B and T cells) and ELISA (cytokines and antibodies).